Moreover, RKIP inhibition in CLL leads to elimination of CXCR4 expression by cancer cells [109], whereas RKIP was shown to play an important role in controlling mast cell-mediated allergic responses, specifically by negatively regulating mast cell activation [110]. Here, CXCR4 is linked to B-cell chronic lymphocytic leukemia.